Jefferies Group LLC reaffirmed their buy rating on shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) in a research note issued to investors on Friday morning. The firm currently has a $16.00 target price on the stock.

Several other analysts have also issued reports on KPTI. HC Wainwright reissued a buy rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, March 17th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 21st. Wedbush reissued an outperform rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, April 5th. Robert W. Baird reissued an outperform rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, April 6th. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $18.00 price target on shares of Karyopharm Therapeutics in a research report on Monday, May 15th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Karyopharm Therapeutics presently has an average rating of Buy and an average target price of $14.46.

Shares of Karyopharm Therapeutics (NASDAQ KPTI) traded up 0.11% on Friday, hitting $9.45. 162,858 shares of the company’s stock were exchanged. Karyopharm Therapeutics has a 12 month low of $6.27 and a 12 month high of $14.63. The stock’s 50 day moving average is $9.29 and its 200 day moving average is $10.20. The firm’s market cap is $445.27 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.04. Karyopharm Therapeutics had a negative net margin of 43,995.59% and a negative return on equity of 79.84%. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.02 million. During the same period last year, the firm earned ($0.75) EPS. On average, equities analysts predict that Karyopharm Therapeutics will post ($2.68) earnings per share for the current year.

WARNING: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/07/17/karyopharm-therapeutics-inc-nasdaqkpti-given-buy-rating-at-jefferies-group-llc.html.

A number of hedge funds have recently bought and sold shares of KPTI. Teza Capital Management LLC purchased a new stake in Karyopharm Therapeutics during the first quarter worth $169,000. Swiss National Bank raised its stake in Karyopharm Therapeutics by 10.9% in the first quarter. Swiss National Bank now owns 40,850 shares of the company’s stock worth $525,000 after buying an additional 4,000 shares during the period. Bank of New York Mellon Corp raised its stake in Karyopharm Therapeutics by 61.7% in the first quarter. Bank of New York Mellon Corp now owns 181,602 shares of the company’s stock worth $2,332,000 after buying an additional 69,315 shares during the period. C WorldWide Group Holding A S raised its stake in Karyopharm Therapeutics by 30.2% in the first quarter. C WorldWide Group Holding A S now owns 16,928 shares of the company’s stock worth $217,000 after buying an additional 3,928 shares during the period. Finally, Wells Fargo & Company MN raised its stake in Karyopharm Therapeutics by 114.6% in the first quarter. Wells Fargo & Company MN now owns 43,606 shares of the company’s stock worth $560,000 after buying an additional 23,284 shares during the period. 57.09% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.